LK 002
Alternative Names: LK-002Latest Information Update: 19 Nov 2025
At a glance
- Originator LiveKidney.Bio
- Class Immunotherapies; Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Kidney disorders; Lupus nephritis
Most Recent Events
- 19 Nov 2025 Discontinued - Clinical-Phase-Unknown for Lupus nephritis (Parenteral) (Livekidney.bio pipeline, November 2025)
- 10 Nov 2025 Discontinued - Clinical-Phase-Unknown for Kidney disorders (Parenteral) (Livekidney.bio pipeline, November 2025)
- 28 Mar 2025 Clinical trials in Kidney disorders (Parenteral) prior to March 2025 (Livekidney.bio Pipeline, March 2025)